A pre-specified subgroup analysis of the VESALIUS-CV trial demonstrates that the PCSK9 inhibitor evolocumab significantly reduces major adverse cardiovascular events and all-cause mortality in high-risk patients with diabetes who do not have established atherosclerosis, supporting earlier and more intensive lipid-lowering therapy.
CardiologyENDOCRINOLOGYTRIALS < class="penci-entry-title entry-title grid-title penci_grid_title">Evolocumab cuts heart events in patients with diabetes but no CVD